{"product_id":"obsessive-compulsive-disorder-isbn-9780470711255","title":"Obsessive Compulsive Disorder","description":"\u003cp\u003eObsessive compulsive disorder (OCD) remains one of the most challenging disorders of the brain.\u003c\/p\u003e \u003cp\u003eContemporary conceptualization and therapeutic strategies are undergoing a revolution as a result of new insights derived from modern technological advances. This book was conceived in order to present this revolution to the reader. It covers current theories regarding the etiology of OCD, what is known about the genetics of this disorder, evidence from neuroimaging and a discussion of potential endophenotypes.  There is an evaluation of current treatment approaches for the disorder, encompassing psychological, psychopharmacological and physical interventions, as well as a discussion of treatment resistance.  The book considers methodological issues, plus reviews of OCD in pediatric populations.  A summary chapter highlights some potential research avenues, in a discussion of the future directions in OCD. \u003c\/p\u003e \u003cp\u003eRather than provide comprehensive coverage, repeating material from standard psychiatry textbooks, this book focuses on recent information and its application, distinguishing it from other titles.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIf you work in children with OCD,\u003c\/li\u003e \u003cli\u003eIf you are interested in genetics, neurocognition or brain imaging,\u003c\/li\u003e \u003cli\u003eIf you work with patients and would like to improve your assessment in OCD and OCD Spectrum disorders, to update your therapeutic strategies and to get a handle on cutting edge developments in this intriguing field,\u003c\/li\u003e \u003cli\u003eIf you are planning a research project in OCD and would like to get some hints from people who are research leaders in this field and also learn about methodological issues specific to OCD research,\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ethen this book will be a valuable resource.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eA concise overview of the current state of the art in OCD assessment and treatment, including physical interventions and treatment resistance\u003c\/li\u003e \u003cli\u003eFocuses on scientific advances (including specific methodological issues) and how they can inform and benefit clinical practice\u003c\/li\u003e \u003cli\u003eLooks critically and broadly at the diagnostic classification, including the ongoing revision of the two major international systems \u003c\/li\u003e \u003cli\u003eWritten by an A-list team of experts in the field who have a track record of being engaging authors\u003c\/li\u003e \u003c\/ul\u003e  List of Contributors xii  \u003cp\u003eIntroduction xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 1 ASSESSMENT AND TREATMENT\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Assessment 3\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJose M. Menchon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 3\u003c\/p\u003e \u003cp\u003eDetecting OCD 5\u003c\/p\u003e \u003cp\u003eScreening in clinical interview 7\u003c\/p\u003e \u003cp\u003eStructured interviews 8\u003c\/p\u003e \u003cp\u003eClinical assessment of obsessive-compulsive symptoms 9\u003c\/p\u003e \u003cp\u003eYale–brown obsessive-compulsive scale 10\u003c\/p\u003e \u003cp\u003eDimensional yale–brown obsessive-compulsive scale (DY–BOCS) 11\u003c\/p\u003e \u003cp\u003eLeyton obsessional inventory (LOI) 12\u003c\/p\u003e \u003cp\u003eMaudsley obsessional-compulsive inventory (MOCI) 13\u003c\/p\u003e \u003cp\u003ePadua inventory (PI) 13\u003c\/p\u003e \u003cp\u003eObsessive compulsive inventory (OCI) 14\u003c\/p\u003e \u003cp\u003eInsight 14\u003c\/p\u003e \u003cp\u003eRating insight 15\u003c\/p\u003e \u003cp\u003eAssessment of the risk of suicide 17\u003c\/p\u003e \u003cp\u003eDifferential diagnosis, comorbidities and related disorders 18\u003c\/p\u003e \u003cp\u003eOrganic brain disorders 19\u003c\/p\u003e \u003cp\u003eSchizophrenia 20\u003c\/p\u003e \u003cp\u003eDepression 20\u003c\/p\u003e \u003cp\u003eHypochondriasis 20\u003c\/p\u003e \u003cp\u003ePhobias 21\u003c\/p\u003e \u003cp\u003eTourette disorder and tic disorders 21\u003c\/p\u003e \u003cp\u003eObsessive-compulsive personality disorder (OCPD) 21\u003c\/p\u003e \u003cp\u003eBody dysmorphic disorder (BDD) 21\u003c\/p\u003e \u003cp\u003eHoarding 22\u003c\/p\u003e \u003cp\u003eOther disorders 22\u003c\/p\u003e \u003cp\u003eConclusions 22\u003c\/p\u003e \u003cp\u003eReferences 23\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Pharmacotherapy of obsessive-compulsive disorder 31\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eEric H. Decloedt and Dan J. Stein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 31\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of clomipramine 32\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of fluvoxamine 32\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of fluoxetine 33\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of paroxetine 34\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of sertraline 34\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of citalopram\/escitalopram 34\u003c\/p\u003e \u003cp\u003ePlacebo-controlled studies of venlafaxine 35\u003c\/p\u003e \u003cp\u003eImproving early response in OCD 35\u003c\/p\u003e \u003cp\u003eSpecial populations: children 36\u003c\/p\u003e \u003cp\u003eClomipramine 36\u003c\/p\u003e \u003cp\u003eFluvoxamine 36\u003c\/p\u003e \u003cp\u003eFluoxetine 36\u003c\/p\u003e \u003cp\u003eParoxetine 37\u003c\/p\u003e \u003cp\u003eSertraline 37\u003c\/p\u003e \u003cp\u003eCitalopram 38\u003c\/p\u003e \u003cp\u003eMeta-analyses 38\u003c\/p\u003e \u003cp\u003eTolerability of clomipramine and serotonin reuptake inhibitors 40\u003c\/p\u003e \u003cp\u003eOptimal dose of treatment 41\u003c\/p\u003e \u003cp\u003eDuration of treatment 42\u003c\/p\u003e \u003cp\u003eRefractory OCD 43\u003c\/p\u003e \u003cp\u003eIncreased dose of SSRI 43\u003c\/p\u003e \u003cp\u003eAugmentation of SSRI treatment with antipsychotics 44\u003c\/p\u003e \u003cp\u003eOther drugs 45\u003c\/p\u003e \u003cp\u003eAlternative modes of administration of SSRIs 46\u003c\/p\u003e \u003cp\u003eCombining SRIs 46\u003c\/p\u003e \u003cp\u003eSwitching SSRIs 46\u003c\/p\u003e \u003cp\u003eAdding psychotherapy 47\u003c\/p\u003e \u003cp\u003eFuture therapeutic options 47\u003c\/p\u003e \u003cp\u003eConclusion 48\u003c\/p\u003e \u003cp\u003eReferences 48\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Cognitive behavioural therapy in obsessive-compulsive disorder: state of the art 58\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMartin E. Franklin, Addie Goss and John S. March\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eTheoretical models 58\u003c\/p\u003e \u003cp\u003eTreatment 60\u003c\/p\u003e \u003cp\u003eExposure plus response prevention (ERP) 60\u003c\/p\u003e \u003cp\u003eCognitive therapies 63\u003c\/p\u003e \u003cp\u003eERP plus medication 63\u003c\/p\u003e \u003cp\u003eOCD protocols 64\u003c\/p\u003e \u003cp\u003eAssessment 64\u003c\/p\u003e \u003cp\u003eAdult ERP protocol 65\u003c\/p\u003e \u003cp\u003ePaediatric ERP protocol 67\u003c\/p\u003e \u003cp\u003eDissemination 67\u003c\/p\u003e \u003cp\u003eFuture research 69\u003c\/p\u003e \u003cp\u003eSummary 69\u003c\/p\u003e \u003cp\u003eReferences 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Electroconvulsive therapy, transcranial magnetic stimulation and deep brain stimulation in OCD 75\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRianne M. Blom, Martijn Figee, Nienke Vulink and Damiaan Denys\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 75\u003c\/p\u003e \u003cp\u003eElectroconvulsive therapy 75\u003c\/p\u003e \u003cp\u003eTranscranial magnetic stimulation 76\u003c\/p\u003e \u003cp\u003eMechanism of action 77\u003c\/p\u003e \u003cp\u003eEfficacy of rTMS in OCD 77\u003c\/p\u003e \u003cp\u003eSide effects and safety 84\u003c\/p\u003e \u003cp\u003eConclusion and future directions 85\u003c\/p\u003e \u003cp\u003eLesioning 85\u003c\/p\u003e \u003cp\u003eDeep brain stimulation 86\u003c\/p\u003e \u003cp\u003eEfficacy of DBS in OCD 86\u003c\/p\u003e \u003cp\u003eMechanism of action of DBS in OCD 92\u003c\/p\u003e \u003cp\u003eSide effects of DBS in OCD 92\u003c\/p\u003e \u003cp\u003eFollow-up treatment 94\u003c\/p\u003e \u003cp\u003eConclusions: DBS 94\u003c\/p\u003e \u003cp\u003eConclusion 94\u003c\/p\u003e \u003cp\u003eAcknowledgements 95\u003c\/p\u003e \u003cp\u003eReferences 95\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Approaches to treatment resistance 99\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStefano Pallanti, Giacomo Grassi and Andrea Cantisani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eTerminological problems and operational definitions 100\u003c\/p\u003e \u003cp\u003ePharmacological strategies in resistant OCD 103\u003c\/p\u003e \u003cp\u003eSwitching 103\u003c\/p\u003e \u003cp\u003eInfusion therapy 104\u003c\/p\u003e \u003cp\u003eCognitive behavioural therapy 105\u003c\/p\u003e \u003cp\u003eSerotoninergic agents 106\u003c\/p\u003e \u003cp\u003eDopaminergic agents 108\u003c\/p\u003e \u003cp\u003eGlutamatergic agents 113\u003c\/p\u003e \u003cp\u003eOpioids 115\u003c\/p\u003e \u003cp\u003ePhysical therapies 115\u003c\/p\u003e \u003cp\u003eElectroconvulsive therapy (ECT) 115\u003c\/p\u003e \u003cp\u003eRepetitive transcranial magnetic stimulation (rTMS) 116\u003c\/p\u003e \u003cp\u003eDeep brain stimulation (DBS) 116\u003c\/p\u003e \u003cp\u003eFamily intervention 117\u003c\/p\u003e \u003cp\u003eConclusions and future perspectives 117\u003c\/p\u003e \u003cp\u003eReferences 118\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 2 CLINICAL SPOTLIGHTS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Subtypes and spectrum issues 135\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eEric Hollander, Steven Poskar and Adriel Gerard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe obsessive-compulsive spectrum 135\u003c\/p\u003e \u003cp\u003eIntroduction 135\u003c\/p\u003e \u003cp\u003eCluster approach 135\u003c\/p\u003e \u003cp\u003eCompulsivity and impulsivity 137\u003c\/p\u003e \u003cp\u003eRepetitive behaviour domain 138\u003c\/p\u003e \u003cp\u003eDetermining placement of proposed OCSDs using cross-cutting domains 139\u003c\/p\u003e \u003cp\u003eObsessive-compulsive spectrum nosology 144\u003c\/p\u003e \u003cp\u003eOCD subtypes: understanding the heterogeneity of OCD 148\u003c\/p\u003e \u003cp\u003eDimensional approach 148\u003c\/p\u003e \u003cp\u003eAssociated symptom domains 150\u003c\/p\u003e \u003cp\u003eCompulsive hoarding: OCPD, OCD subtype, dimension, OCSD or something else? 151\u003c\/p\u003e \u003cp\u003eConclusion 154\u003c\/p\u003e \u003cp\u003eReferences 154\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Paediatric OCD: developmental aspects and treatment considerations 160\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDaniel A. Geller, Alyssa L. Faro, Ashley R. Brown and Hannah C. Levy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 160\u003c\/p\u003e \u003cp\u003eEpidemiology 160\u003c\/p\u003e \u003cp\u003eAetiological considerations 161\u003c\/p\u003e \u003cp\u003eGenetic factors 161\u003c\/p\u003e \u003cp\u003eNon-genetic factors 164\u003c\/p\u003e \u003cp\u003eAetiology: summary 167\u003c\/p\u003e \u003cp\u003eClinical features 167\u003c\/p\u003e \u003cp\u003eGender and age at onset 168\u003c\/p\u003e \u003cp\u003eElaboration of phenotypic dimensions 168\u003c\/p\u003e \u003cp\u003eComorbid conditions 169\u003c\/p\u003e \u003cp\u003eNeuropsychological endophenotypes 170\u003c\/p\u003e \u003cp\u003eClinical features: summary 170\u003c\/p\u003e \u003cp\u003eClinical assessment 171\u003c\/p\u003e \u003cp\u003eDifferential diagnosis 172\u003c\/p\u003e \u003cp\u003eNormal development 172\u003c\/p\u003e \u003cp\u003eOther psychiatric disorders 172\u003c\/p\u003e \u003cp\u003eTreatment 173\u003c\/p\u003e \u003cp\u003ePharmacotherapy 174\u003c\/p\u003e \u003cp\u003eModerating effect of comorbid conditions 175\u003c\/p\u003e \u003cp\u003eMultimodal treatment 176\u003c\/p\u003e \u003cp\u003eMedication augmentation strategies in treatment resistance 177\u003c\/p\u003e \u003cp\u003eSafety and tolerability 178\u003c\/p\u003e \u003cp\u003eTreatment: summary 178\u003c\/p\u003e \u003cp\u003eCourse and prognosis 179\u003c\/p\u003e \u003cp\u003eConclusions and future research 179\u003c\/p\u003e \u003cp\u003eAcknowledgements 180\u003c\/p\u003e \u003cp\u003eReferences 180\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSECTION 3 RESEARCH SPOTLIGHTS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Methodological issues for clinical treatment trials in obsessive-compulsive disorder 193\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSamar Reghunandanan and Naomi A. Fineberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 193\u003c\/p\u003e \u003cp\u003eRandomized controlled trials 194\u003c\/p\u003e \u003cp\u003eThe rationale of placebo 196\u003c\/p\u003e \u003cp\u003eRecruitment criteria 199\u003c\/p\u003e \u003cp\u003eDiagnosis 199\u003c\/p\u003e \u003cp\u003eOCD dimensions and subtypes 200\u003c\/p\u003e \u003cp\u003eThe problem of comorbidity 201\u003c\/p\u003e \u003cp\u003eRating scales for OCD trials 203\u003c\/p\u003e \u003cp\u003eEvaluating anxiety and depression in OCD 204\u003c\/p\u003e \u003cp\u003eMeasuring response and remission 205\u003c\/p\u003e \u003cp\u003eRelapse prevention 207\u003c\/p\u003e \u003cp\u003eTreatment-resistant OCD 208\u003c\/p\u003e \u003cp\u003ePsychological treatment trials 209\u003c\/p\u003e \u003cp\u003eIntegrated pharmacological and psychological treatments in OCD 210\u003c\/p\u003e \u003cp\u003eHealth-related quality of life 211\u003c\/p\u003e \u003cp\u003eSummary 211\u003c\/p\u003e \u003cp\u003eReferences 212\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Serotonin and beyond: a neurotransmitter perspective of OCD 220\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAnat Abudy, Alzbeta Juven-Wetzler, Rachel Sonnino and Joseph Zohar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSerotonin 221\u003c\/p\u003e \u003cp\u003eSerotonin and metabolite concentrations in OCD – 30 years later 222\u003c\/p\u003e \u003cp\u003ePharmacological challenge tests 224\u003c\/p\u003e \u003cp\u003ePharmacotherapy 225\u003c\/p\u003e \u003cp\u003eAnimal models and the role of serotonin 226\u003c\/p\u003e \u003cp\u003eDopamine 227\u003c\/p\u003e \u003cp\u003eDopamine and metabolite concentrations in humans 227\u003c\/p\u003e \u003cp\u003ePharmacological challenge tests 228\u003c\/p\u003e \u003cp\u003ePharmacotherapy 229\u003c\/p\u003e \u003cp\u003eAnimal models and the role of dopamine 231\u003c\/p\u003e \u003cp\u003eGlutamate 232\u003c\/p\u003e \u003cp\u003eThe glutamatergic influence 232\u003c\/p\u003e \u003cp\u003eGlutamate and metabolite concentrations in humans 232\u003c\/p\u003e \u003cp\u003eAnimal models and the role of glutamate 233\u003c\/p\u003e \u003cp\u003eSerotonin: is it the one to blame? 233\u003c\/p\u003e \u003cp\u003eThe puzzle of antipsychotics and OCD: Is dopamine the answer? 234\u003c\/p\u003e \u003cp\u003eSo, is it a question of location? (Or . . . location, location, location?) 234\u003c\/p\u003e \u003cp\u003eReferences 235\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Brain imaging 244\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid R. Rosenberg, Phillip C. Easter and Georgia Michalopoulou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eNeuroimaging modalities 244\u003c\/p\u003e \u003cp\u003eStructural assessment 244\u003c\/p\u003e \u003cp\u003eFunctional neurochemical assessment 245\u003c\/p\u003e \u003cp\u003eStructural assessment of OCD 246\u003c\/p\u003e \u003cp\u003eTotal brain volume\/ventricles 246\u003c\/p\u003e \u003cp\u003eBasal ganglia 246\u003c\/p\u003e \u003cp\u003ePrefrontal cortex 248\u003c\/p\u003e \u003cp\u003eMedial temporal-limbic cortex 252\u003c\/p\u003e \u003cp\u003ePituitary 253\u003c\/p\u003e \u003cp\u003eSupramarginal gyrus 253\u003c\/p\u003e \u003cp\u003eWhite matter 254\u003c\/p\u003e \u003cp\u003eFunctional neuroimaging studies of OCD 255\u003c\/p\u003e \u003cp\u003eNeurochemistry 258\u003c\/p\u003e \u003cp\u003eSerotonin 258\u003c\/p\u003e \u003cp\u003eN-acetyl-aspartate 258\u003c\/p\u003e \u003cp\u003eCholine 259\u003c\/p\u003e \u003cp\u003eCreatine\/phosphocreatine 262\u003c\/p\u003e \u003cp\u003eGlutamate 262\u003c\/p\u003e \u003cp\u003eConclusion 266\u003c\/p\u003e \u003cp\u003eAcknowledgements 267\u003c\/p\u003e \u003cp\u003eReferences 268\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 The genetics of obsessive-compulsive disorder: current status 277\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid L. Pauls\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 277\u003c\/p\u003e \u003cp\u003eTwin studies 277\u003c\/p\u003e \u003cp\u003eFamily studies 279\u003c\/p\u003e \u003cp\u003eFamily history studies 280\u003c\/p\u003e \u003cp\u003eFamily interview studies 280\u003c\/p\u003e \u003cp\u003eSegregation analyses 284\u003c\/p\u003e \u003cp\u003eCandidate gene studies 285\u003c\/p\u003e \u003cp\u003eGenetic linkage studies 290\u003c\/p\u003e \u003cp\u003eFuture work 291\u003c\/p\u003e \u003cp\u003eAcknowledgements 292\u003c\/p\u003e \u003cp\u003eReferences 292\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Neurocognitive angle: the search for endophenotypes 300\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSamuel R. Chamberlain and Lara Menzies\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 300\u003c\/p\u003e \u003cp\u003eHeritability of OCD 301\u003c\/p\u003e \u003cp\u003eThe concept of an endophenotype 302\u003c\/p\u003e \u003cp\u003eApplying the endophenotype construct to OCD 305\u003c\/p\u003e \u003cp\u003eDomains of interest in hierarchical modelling of OCD 307\u003c\/p\u003e \u003cp\u003eCognition 307\u003c\/p\u003e \u003cp\u003eNeuroimaging 308\u003c\/p\u003e \u003cp\u003eSearching for endophenotypes of OCD 311\u003c\/p\u003e \u003cp\u003eCognition 311\u003c\/p\u003e \u003cp\u003eNeuroimaging 313\u003c\/p\u003e \u003cp\u003eOther potential endophenotypes 316\u003c\/p\u003e \u003cp\u003eSummary 317\u003c\/p\u003e \u003cp\u003eAcknowledgements and disclosures 319\u003c\/p\u003e \u003cp\u003eReferences 320\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Conclusion and future directions 327\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJoseph Zohar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReferences 329\u003c\/p\u003e \u003cp\u003eIndex 331\u003c\/p\u003e \"This is an extremely useful book for anyone who wishes to extend their knowledge and develop services for OCD.As well as presenting the science behind OCD, the outcomes of various therapeutic interventons are also examined.This is a useful additionl to the literature and would recommend it to all adult and child psychiatrists who may wonder how to treat these patients.\" (\u003cb\u003eBritish Journal of Psychiatry, 2013\u003c\/b\u003e)  \u003cp\u003eJoseph Zohar is Department Chair of the Division of Psychiatry at Chaim Sheba Medical Center, Tel Hashomer, Israel. He is also Professor of Psychiatry at the  Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.  He is President of the European College of Neuropharmacology, Associate editor of the World Journal of Biological Psychiatry and International editor of CNS.\u003c\/p\u003e \u003cp\u003eDr. Zohar has received numerous awards, including: Fogarty International Research Fellowship Award, in 1984; A.E. Bennet Award for Clinical Research in 1986; European College of Neuropsychopharmacology – Lilly Neuroscience Award for Clinical Research in 1998; and World Federation Society of Biological Psychiatry on excellency in education in 2001.\u003c\/p\u003e  \u003cp\u003eObsessive compulsive disorder (OCD) remains one of the most challenging disorders of the brain.\u003c\/p\u003e \u003cp\u003eContemporary conceptualization and therapeutic strategies are undergoing a revolution as a result of new insights derived from modern technological advances. This book was conceived in order to present this revolution to the reader. It covers current theories regarding the etiology of OCD, what is known about the genetics of this disorder, evidence from neuroimaging and a discussion of potential endophenotypes.  There is an evaluation of current treatment approaches for the disorder, encompassing psychological, psychopharmacological and physical interventions, as well as a discussion of treatment resistance.  The book considers methodological issues, plus reviews of OCD in pediatric populations.  A summary chapter highlights some potential research avenues, in a discussion of the future directions in OCD. \u003c\/p\u003e \u003cp\u003eRather than provide comprehensive coverage, repeating material from standard psychiatry textbooks, this book focuses on recent information and its application, distinguishing it from other titles.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIf you work in children with OCD,\u003c\/li\u003e \u003cli\u003eIf you are interested in genetics, neurocognition or brain imaging,\u003c\/li\u003e \u003cli\u003eIf you work with patients and would like to improve your assessment in OCD and OCD Spectrum disorders, to update your therapeutic strategies and to get a handle on cutting edge developments in this intriguing field,\u003c\/li\u003e \u003cli\u003eIf you are planning a research project in OCD and would like to get some hints from people who are research leaders in this field and also learn about methodological issues specific to OCD research,\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ethen this book will be a valuable resource.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eA concise overview of the current state of the art in OCD assessment and treatment, including physical interventions and treatment resistance\u003c\/li\u003e \u003cli\u003eFocuses on scientific advances (including specific methodological issues) and how they can inform and benefit clinical practice\u003c\/li\u003e \u003cli\u003eLooks critically and broadly at the diagnostic classification, including the ongoing revision of the two major international systems \u003c\/li\u003e \u003cli\u003eWritten by an A-list team of experts in the field who have a track record of being engaging authors\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989706948837,"sku":"NP9780470711255","price":124.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470711255.jpg?v=1761785185","url":"https:\/\/k12savings.com\/products\/obsessive-compulsive-disorder-isbn-9780470711255","provider":"K12savings","version":"1.0","type":"link"}